334 related articles for article (PubMed ID: 34125356)
1. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.
Kim YS; Brar S; D'Albo N; Dey A; Shah S; Ganatra S; Dani SS
Cardiovasc Drugs Ther; 2022 Oct; 36(5):915-924. PubMed ID: 34125356
[TBL] [Abstract][Full Text] [Related]
2. The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data.
Lerman TT; Greenberg N; Fishman B; Goldman A; Talmor-Barkan Y; Bauer M; Goldberg I; Goldberg E; Kornowski R; Krause I; Levi A; Cohen E
Int J Cardiol; 2024 Feb; 397():131613. PubMed ID: 38030039
[TBL] [Abstract][Full Text] [Related]
3. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
Dani SS; Ganatra S; Vaduganathan M
Int J Cardiol; 2021 Jan; 323():188-191. PubMed ID: 32841619
[TBL] [Abstract][Full Text] [Related]
4. Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry.
Matsumoto S; McMurray JJV; Nasu T; Ishii S; Kagiyama N; Kida K; Fujimoto W; Kikuchi A; Ijichi T; Shibata T; Ikeda T; Kanaoka K
J Cardiol; 2024 Aug; 84(2):133-140. PubMed ID: 38000538
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
6. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Shi V; Senni M; Streefkerk H; Modgill V; Zhou W; Kaplan A
Int J Cardiol; 2018 Aug; 264():118-123. PubMed ID: 29776559
[TBL] [Abstract][Full Text] [Related]
7. Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis.
Charuel E; Menini T; Bedhomme S; Pereira B; Piñol-Domenech N; Bouchant S; Boussageon R; Bœuf-Gibot S; Vaillant-Roussel H
Pharmacol Res Perspect; 2021 Oct; 9(5):e00844. PubMed ID: 34617669
[TBL] [Abstract][Full Text] [Related]
8. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Gatti M; Antonazzo IC; Diemberger I; De Ponti F; Raschi E
Eur J Prev Cardiol; 2021 Aug; 28(9):983-989. PubMed ID: 34402868
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction.
Khan MN; Soomro NA; Naseeb K; Bhatti UH; Rauf R; Balouch IJ; Moazzam A; Bashir S; Ashraf T; Karim M
BMC Cardiovasc Disord; 2023 Mar; 23(1):133. PubMed ID: 36915075
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis investigating the efficacy and adverse events linked to sacubitril-valsartan in various heart failure subtypes.
Ji Q
Clin Cardiol; 2024 Feb; 47(2):e24192. PubMed ID: 38013641
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.
Zhou W; Yang X; Jin J; Cheng M; Li Y; Bai Y; Xu J
Int Urol Nephrol; 2024 Jan; 56(1):181-190. PubMed ID: 37195574
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
14. Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
Huang Y; Zhang Y; Ma L; Zhou H; Fang C; Chen C
J Cardiovasc Pharmacol; 2021 Aug; 78(2):202-210. PubMed ID: 33929386
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.
Yang HR; Xu XD; Shaikh AS; Zhou BT
Ann Pharmacother; 2023 Aug; 57(8):907-917. PubMed ID: 36475871
[TBL] [Abstract][Full Text] [Related]
16. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
17. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
[TBL] [Abstract][Full Text] [Related]
18. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Sacubitril/Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction during the Vulnerable Phase: A Multicenter, Assessor-Blinded, Prospective, Observational, Cohort Study.
He Y; Lu X; Zheng Y; Song M; Shen B; Nienaber CA; Chen G; Wu F; Zheng J; Zhang W; Wang Y; Li X; Wen H; Yu X; Zhou Y
Cardiology; 2021; 146(3):335-344. PubMed ID: 33780933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
